European Archives - Page 726 of 1074 - European Medical Journal

Preview of the European Society for Medical Oncology (ESMO) 2018 Congress

From 19th–23rd October, Munich, Germany will host this year’s edition of the annual ESMO Congress at the world-famous Messe Munich convention centre.

Johnson & Johnson Vision Encourages Public to #spotlightsight for World Sight Day

Sight is arguably the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift.

European Medical Journal Presents: EMJ Cardiology 6.1

The publication of EMJ Cardiology 6.1 is now available and features a full review of the European Society of Cardiology (ESC) 2018 Congress…

EMJ Cardiology 6.1 2018

As well as capturing the event’s bustling atmosphere within the pages of its Congress Review, this year’s eJournal presents key research, discussion, and…

Fibre-Optic Contact Force Catheter Efficiency and Effectiveness in Paroxysmal Atrial Fibrillation Ablation from a Large, Multinational, Prospective Registry (ABLATOR)

Over recent years, in response to the widespread use of contact force (CF) ablation catheters for the treatment of atrial fibrillation, numerous studies…

Review of the European Society of Cardiology Congress 2018

Known as the largest cardiovascular conference in the world, it was apt that the high standards of the European Society of Cardiology (ESC) were matched…

Guidelines, Clinical Evidence, and Real-Life Practice: How to Find Your Way in Managing Hypercholesterolaemia

Prof Masana presented evidence that low-density lipoprotein (LDL) cholesterol is a causal factor for atherosclerosis and that cardiovascular disease (CVD…

Impact of a Cardiac Rehabilitation Programme After a Myocardial Infarction in Individuals Not Undergoing Revascularisation: New Horizons for a Time-Tested Intervention

Cardiac rehabilitation (CR) plays a pivotal role in the contemporary management of myocardial infarction (MI) patients and several studies have…

Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor

Andexanet alfa is a modified factor Xa (FXa) drug designed to bind and sequester FXa inhibitors and thus reverse anticoagulation…

Congress Interview from the ESC Congress 2018

During the ESC 2018 Congress, we met with EMJ Cardiology’s Editor-in-Chief, Dr Çetin Erol, to ask about his experience of this year’s event and his…